"Suggestions for Business Development in S. Korea's Healthcare Industry"
MediHeroes shared the latest status and outlook of Korea’s Biotechnology to the GHA - German Health Alliance members on July 11th. We'd like to thank Mr. Ben Schalke, senior director from Midas Pharma and GHA in Germany for inviting Ms. Joanne J. Lee as a speaker to the webinar. We look forward to upcoming networking sessions between the German Health Alliance members and Korean biotechnology companies in the near future.
Check out the topics and the invited speakers at the webinar.
Joanne Lee, MediHeroes, CEO
Topic: Biotechnology as the top 3 growth engines for Korea over the past 5 years
· BA Consumer Science & MBA in Marketing from SNU, Korea
· Mercedes / Daimler AG, Strategic Marketing Manager, Germany & Hong Kong
· Frost & Sullivan (Consulting), CA, USA
- GM of Boditech Med Inc. (in-vitro Diagnostic), Korea
·
Christian Groeger, Eppendorf, Managing Director in Korea
Topic: “Sunshine or Rain? Korea’s Life Science industry in transition”
· 2012 – today: Managing Director, Eppendorf Korea
· 2010 – 2012, Client Relationship Manager, Fiducia Management Consultants
· 2008 – 2010, Regional Manager, Machwürth Team International, Regional Manager for MTI Asia in Shanghai
· 2006 – 2007, Office Manager/GD Assistant, Taipeh Vertretung in der BRD, Assistant to General Director
· Chinese: Nanjing University, Chinese Studies, Cultural Studies
· Beijing Film Academy: Chinese Studies, Japanese Studies, Kobe University
· Economics: Universität Hamburg, Int. Business and Economics with China Focus
· Economics: Fudan University Shanghai, Business and Economics with China Focus
· Chinese Studies, Japanese Studies, Korean, Politics, Universität Hamburg
Steffen Tropitzsch, CFM
Topic: “What is needed so that Korea will play a more important role for your business?”
· 1788: Ältestes dtsch. Chemie-Unternehmen
· 1891: 4. Generation eingestiegen, 7. Generation insgesamt
· Spezialitätenhandel für Biotech, Crop Science
· 12 Mitarbeitende, >10 Mio EU Umsatz
· Sourcing aus 50 Ländern, z.B. Indien
· „Know-How ist Treiber, nicht Preis.“
· GDP Vorreiter in Bayern
· EU und USA Vorreiter für Technologien
· Kunden: Innovatoren, Big Pharma, nicht Generika
· Erst R&D, dann Aufbau von Kapazitäten für Commercial
· Rohstoffe, Payloads for ADCs
Steven Cho, GID Partners, VP Commercial Strategy
Topic: “What kind of support do innovative Korean companies require mostly?”
· Indiana University - Kelley School of Business, Executive MBA
· Inha University (Korea), BA in Bioengineering
· ASA College / Brooklyn New York, ASA College, BA of Biz Admin
· Almost 11 years at Hanmi Pharmaceuticals
· Global business General manager
· Global business development : Finished product (Gx, IMD, Combination), API, CDMO
· Asia Part Leader, MENA, ASIA Area manager
To see the original posting at LinkedIn, click the link below.
Comments